



**Denver, Colorado – 2004 (N=300)**


**Figure A. Age of GISP participants, in years, 2004**




**Figure B. Race/ethnicity of GISP participants, 2004**



**Figure C. Percentage of GISP participants identifying as men who have sex with men, 1988–2004**




**Figure D. Reason for visit among GISP participants, 2004**




## Denver, Colorado – 2004 (N=300)


**Figure E. Previous episode of gonorrhea among GISP participants, 1991–2004**




**Figure F. Drugs used to treat gonorrhea among GISP participants, 2004**



**Figure G. Drugs used to treat *Chlamydia trachomatis* infection among GISP participants, 2004**



**Figure H. Resistance to penicillin and tetracycline among GISP isolates, 2004**




**Denver, Colorado – 2004 (N=300)**


**Figure I. Decreased susceptibility to ceftriaxone among GISP isolates, 1988–2004**

No isolates with decreased susceptibility to ceftriaxone have been identified at this clinic.

**Figure J. Decreased susceptibility to cefixime among GISP isolates, 1992–2004**




**Figure K. Intermediate resistance and resistance to ciprofloxacin among GISP isolates, 1990–2004**



Note: Susceptibility to ciprofloxacin first measured in 1990.

**Figure L. Decreased susceptibility to azithromycin among GISP isolates, 1992–2004**



Note: Susceptibility to azithromycin first measured in 1992.

Note: Decreased susceptibility to azithromycin is defined here as  $\geq 1.0 \mu\text{g}/\text{ml}$ .  
No NCCLS criteria currently exist.